AR063232A1 - Pirido (2,3) indoles como inhibidores de quinasas.composiciones farmaceuticas. - Google Patents
Pirido (2,3) indoles como inhibidores de quinasas.composiciones farmaceuticas.Info
- Publication number
- AR063232A1 AR063232A1 ARP070104481A ARP070104481A AR063232A1 AR 063232 A1 AR063232 A1 AR 063232A1 AR P070104481 A ARP070104481 A AR P070104481A AR P070104481 A ARP070104481 A AR P070104481A AR 063232 A1 AR063232 A1 AR 063232A1
- Authority
- AR
- Argentina
- Prior art keywords
- 3alkyl
- alkyl
- 10alkyl
- 5alkyl
- heteroc3
- Prior art date
Links
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 2
- 150000002475 indoles Chemical class 0.000 title 1
- 239000003112 inhibitor Substances 0.000 title 1
- 125000006527 (C1-C5) alkyl group Chemical group 0.000 abstract 7
- -1 cyano, thio, oxy, hydroxy, carbonyloxy Chemical group 0.000 abstract 6
- 229910052739 hydrogen Inorganic materials 0.000 abstract 5
- 239000001257 hydrogen Substances 0.000 abstract 5
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 5
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 abstract 5
- 125000000008 (C1-C10) alkyl group Chemical group 0.000 abstract 4
- 125000006652 (C3-C12) cycloalkyl group Chemical group 0.000 abstract 4
- 125000003545 alkoxy group Chemical group 0.000 abstract 4
- 125000003282 alkyl amino group Chemical group 0.000 abstract 4
- 125000003118 aryl group Chemical group 0.000 abstract 4
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 abstract 4
- 125000001475 halogen functional group Chemical group 0.000 abstract 4
- 125000000753 cycloalkyl group Chemical group 0.000 abstract 3
- 125000001072 heteroaryl group Chemical group 0.000 abstract 3
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 abstract 3
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 abstract 2
- 125000000217 alkyl group Chemical group 0.000 abstract 2
- 125000004104 aryloxy group Chemical group 0.000 abstract 2
- 125000004429 atom Chemical group 0.000 abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 2
- 125000005553 heteroaryloxy group Chemical group 0.000 abstract 2
- 238000000926 separation method Methods 0.000 abstract 2
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 abstract 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 abstract 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 abstract 1
- 230000000712 assembly Effects 0.000 abstract 1
- 238000000429 assembly Methods 0.000 abstract 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 abstract 1
- 150000001602 bicycloalkyls Chemical group 0.000 abstract 1
- 229910052799 carbon Inorganic materials 0.000 abstract 1
- 150000002148 esters Chemical class 0.000 abstract 1
- 125000004356 hydroxy functional group Chemical group O* 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 229910052757 nitrogen Inorganic materials 0.000 abstract 1
- 229910052760 oxygen Inorganic materials 0.000 abstract 1
- 239000001301 oxygen Substances 0.000 abstract 1
- 239000000651 prodrug Substances 0.000 abstract 1
- 229940002612 prodrug Drugs 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 239000012453 solvate Substances 0.000 abstract 1
- 125000000475 sulfinyl group Chemical group [*:2]S([*:1])=O 0.000 abstract 1
- 229910052717 sulfur Inorganic materials 0.000 abstract 1
- 239000011593 sulfur Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Immunology (AREA)
- Psychiatry (AREA)
- Rheumatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Molecular Biology (AREA)
- Psychology (AREA)
- Biochemistry (AREA)
- Reproductive Health (AREA)
- Oncology (AREA)
- Dermatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Pain & Pain Management (AREA)
- Transplantation (AREA)
- Cardiology (AREA)
- Hematology (AREA)
- Hospice & Palliative Care (AREA)
- Gynecology & Obstetrics (AREA)
- Pregnancy & Childbirth (AREA)
- Urology & Nephrology (AREA)
- Endocrinology (AREA)
- Vascular Medicine (AREA)
- Heart & Thoracic Surgery (AREA)
Abstract
También se suministran composiciones farmacéuticas, conjuntos de elementos (kits) y artículos manufacturados que comprenden tales compuestos, y métodos de uso de los mismos. Reivindicacion 1: Un compuesto, que comprende una formula; o un polimorfo, solvato, éster, tautomero, enantiomero, sal aceptable para uso farmacéutico o prodroga de! mismo, en donde R2 es -Y2-R13; Y2 está ausente o es una union que provee una separacion de 1 o 2 átomos entre R13 y el anillo al cual Y2 está unido, en donde los átomos de la union que suministra la separacion se seleccionan entre el grupo que consiste de carbono, oxigeno, nitrogeno, y azufre; R4 se selecciona entre el grupo que consiste de hidrogeno, halo, nitro, ciano, tio, oxi, hidroxi, carboniloxi, alcoxi, carbonilo, amino, alquilamino C1-5, alquilo C1-5, haloC1-5alqui!o, carbonilC1-3alquilo, sulfonilC1-3alquilo, aminoC1-5alquilo, arilC1-5alquilo, heteroarilC1-5alquilo, cicloalquilo C3-6 y heteroC3-6cicloalquilo, cada uno sustituido o no sustituido; R5 y R6 se selecciona cada uno en forma independiente entre el grupo que consiste de hidrogeno, halo, nitro, ciano, tio, oxi, hidroxi, alcoxi, ariloxi, heteroariloxi, carbonilo, amino, alquilamino C1-10, sulfonamido, imino, sulfonilo, suIfinilo, alquilo C1-10, haloC1-10alquilo, carbonilC1-3alquilo, tiocarbonilC1-3alquilo, sulfonilC1-3alquilo, sulfinilC1-3alquilo, amino C1-10alquilo, iminoC1-3alquilo, cicloalquilC3-12-alquiloC1-5, heteroC3-12cicloalquil-alquiloC1- 5, arilC1-10alquilo, heteroarilC1-5alquilo, bicicloarilC9-12-alquilo C1-5, heteroC8-12bicicloarilC1-5alquilo, cicloalquilo C3-12, heteroC3-12cicloalquilo, bicicloalquilo C9-12, heteroC3-12bicicloalquilo, arilo, heteroarilo, bicicloarilo C9-12 y heteroC4-12bicicloarilo, cada uno sustituido o no sustituido; R7 se selecciona entre el grupo que consiste de hidrogeno, halo, hidroxi, alcoxi, amino y alquilo C1-5, cada uno sustituido o no sustituido; R12 y R13 se selecciona cada uno en forma independiente entre el grupo que consiste de hidrogeno, halo, nitro, ciano, tio, oxi, hidroxi, alcoxi, ariloxi, heteroariloxi, carbonilo, amino, alquilamino C1-10, sulfonamido, imino, sulfonilo, sulfinilo, alquilo C1-10, haloC1-10alquilo, carbonilC1- 3alquilo, tiocarbonilC1-3alquilo, sulfonilC1-3alquilo, sulfinilC1-3alquilo, amino C1-10alquilo, iminoC1-3alquilo, cicloalquil C3-12-alquilo C1-5, heteroC3-12cicloalquil-alquilo C1-5, arilC1-10alquilo, heteroarilC1-5alquilo, bicicloarilC9-12-alquilo C1-5, heteroC8-12bicicloarilC1-5alquilo, cicloalquilo C3-12, heteroC3-12cicloalquilo, bicicloalquilo C9-12, heteroC3-12bicicloalquilo, arilo, heteroarilo, bicicloarilo C9-12 y heteroC4-12bicicloarilo, cada uno sustituido o no sustituido; o R12 y R13 se toman juntos para formar un anillo sustituido o no sustituido; R16 se selecciona entre el grupo que consiste de amino, alquilamino C1-10, alquilo C1-10, haloC1-10alquilo, hidroxiC1-5alquilo, carbonilC1-3alquilo, tiocarbonilC1-3alquilo, sulfonilC1- 3alquilo, sulfinilC1-3alquilo, aminoC1-10alquilo, cicloalquil C3-12-alquilo C1-5, heteroC3-12cicloalquil-alquilo C1-5, arilC1-10alquilo, heteroarilC1-5alquilo, cicloalquilo C3-12, heteroC3-12cicloalquilo, arilo y heteroarilo, cada uno sustituido o no sustituido; y R23 se selecciona entre el grupo que consiste de hidrogeno, carbonilo, alquilo C1-10, haloC1-10alquilo, carbonilC1-3alquilo, tiocarbonilC1-3alquilo, sulfonilC1-3alquilo, sulfinilC1-3alquilo, amino C1-10alquilo, iminoC1-3alquilo, cicloalquil C3-12-alquilo C1-5, heteroC3-12cicloalquil-alquilo C1-5, arilC1-10alquilo, heteroarilC1-5alquilo, cicloalquilo C3-12, heteroC3-12cicloalquilo, arilo y heteroarilo, cada uno sustituido o no sustituido; o R23 y R12 se toman juntos para formar un anillo sustituido o no sustituido.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US91262507P | 2007-04-18 | 2007-04-18 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR063232A1 true AR063232A1 (es) | 2009-01-14 |
Family
ID=40754069
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP070104481A AR063232A1 (es) | 2007-04-18 | 2007-10-10 | Pirido (2,3) indoles como inhibidores de quinasas.composiciones farmaceuticas. |
Country Status (7)
| Country | Link |
|---|---|
| US (2) | US20090156557A1 (es) |
| EP (1) | EP2223925A1 (es) |
| JP (1) | JP2010505961A (es) |
| AR (1) | AR063232A1 (es) |
| CL (1) | CL2007002919A1 (es) |
| PE (1) | PE20081458A1 (es) |
| TW (1) | TW200823212A (es) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8119655B2 (en) | 2005-10-07 | 2012-02-21 | Takeda Pharmaceutical Company Limited | Kinase inhibitors |
| JP2010505962A (ja) * | 2006-10-09 | 2010-02-25 | 武田薬品工業株式会社 | キナーゼ阻害剤 |
| US20110184178A1 (en) * | 2008-04-16 | 2011-07-28 | Takeda Pharmaceutical Company Limited | Polymorphs of 5-(3-(ethylsulfonyl)phenyl)-3,8-dimethyl-n-(1-methylpiperidin-4-yl)-9h-pyrido[2,3-b]indole-7-carboxamide and methods of use therefor |
| JP2014169273A (ja) * | 2013-02-06 | 2014-09-18 | Tosoh Organic Chemical Co Ltd | 環式芳香族化合物の製造方法 |
| EP3193611B1 (en) | 2014-09-17 | 2021-03-24 | Celgene Car Llc | Mk2 inhibitors and uses thereof |
| HRP20220255T1 (hr) | 2016-10-24 | 2022-04-29 | Astrazeneca Ab | Derivati 6,7,8,9-tetrahidro-3h-pirazolo[4,3-f]izokinolina koji su korisni u liječenju raka |
| LT3494116T (lt) | 2017-01-30 | 2020-01-10 | Astrazeneca Ab | Estrogeno receptorių moduliatoriai |
| US11230551B2 (en) * | 2017-03-16 | 2022-01-25 | Celgene Car Llc | Deuterated analogs of MK2 inhibitors and uses thereof |
| JP7282039B2 (ja) | 2017-03-16 | 2023-05-26 | セルジーン シーエーアール エルエルシー | Ｍｋ２阻害剤、その合成、およびそれに至るまでの中間体 |
Family Cites Families (97)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3710795A (en) | 1970-09-29 | 1973-01-16 | Alza Corp | Drug-delivery device with stretched, rate-controlling membrane |
| GB1429184A (en) | 1972-04-20 | 1976-03-24 | Allen & Hanburys Ltd | Physically anti-inflammatory steroids for use in aerosols |
| US4044126A (en) | 1972-04-20 | 1977-08-23 | Allen & Hanburys Limited | Steroidal aerosol compositions and process for the preparation thereof |
| USRE28819E (en) | 1972-12-08 | 1976-05-18 | Syntex (U.S.A.) Inc. | Dialkylated glycol compositions and medicament preparations containing same |
| JPS54110226A (en) * | 1978-01-25 | 1979-08-29 | Bayer Ag | Dye |
| US4410545A (en) | 1981-02-13 | 1983-10-18 | Syntex (U.S.A.) Inc. | Carbonate diester solutions of PGE-type compounds |
| US4328245A (en) | 1981-02-13 | 1982-05-04 | Syntex (U.S.A.) Inc. | Carbonate diester solutions of PGE-type compounds |
| US4358603A (en) | 1981-04-16 | 1982-11-09 | Syntex (U.S.A.) Inc. | Acetal stabilized prostaglandin compositions |
| US4409239A (en) | 1982-01-21 | 1983-10-11 | Syntex (U.S.A.) Inc. | Propylene glycol diester solutions of PGE-type compounds |
| GB9222253D0 (en) * | 1992-10-23 | 1992-12-09 | Celltech Ltd | Chemical compounds |
| GB9304920D0 (en) * | 1993-03-10 | 1993-04-28 | Celltech Ltd | Chemical compounds |
| US6716575B2 (en) * | 1995-12-18 | 2004-04-06 | Sugen, Inc. | Diagnosis and treatment of AUR1 and/or AUR2 related disorders |
| GB9625184D0 (en) * | 1996-12-04 | 1997-01-22 | Celltech Therapeutics Ltd | Chemical compounds |
| EP1004667B1 (en) * | 1997-08-15 | 2006-10-18 | Hiroshima University | Cell cycle-regulating proteins |
| US7462605B2 (en) * | 1998-01-23 | 2008-12-09 | Celmed Oncology (Usa), Inc. | Phosphoramidate compounds and methods of use |
| US6706491B1 (en) * | 1999-04-09 | 2004-03-16 | The Board Of Trustees Of The University Of Illinois | Reagents and methods for identifying and modulating expression of genes regulated by p21 |
| US20050113460A1 (en) * | 1999-04-30 | 2005-05-26 | The Regents Of The University Of Michigan | Compositions and methods relating to novel compounds and targets thereof |
| US6982265B1 (en) * | 1999-05-21 | 2006-01-03 | Bristol Myers Squibb Company | Pyrrolotriazine inhibitors of kinases |
| IL150388A0 (en) * | 1999-12-24 | 2002-12-01 | Aventis Pharma Ltd | Azaindoles |
| EP1294709A2 (en) * | 2000-01-28 | 2003-03-26 | AstraZeneca AB | Quinoline derivatives and their use as aurora 2 kinase inhibitors |
| IL145756A0 (en) * | 2000-02-05 | 2002-07-25 | Vertex Pharma | Pyrazole derivatives and pharmaceutical compositions containing the same |
| BR0104424A (pt) * | 2000-02-05 | 2002-01-08 | Vertex Pharma | Composições de pirazol úteis como inibidores de erk |
| JP2001302667A (ja) * | 2000-04-28 | 2001-10-31 | Bayer Ag | イミダゾピリミジン誘導体およびトリアゾロピリミジン誘導体 |
| US6555329B2 (en) * | 2000-06-09 | 2003-04-29 | Boehringer Ingelheim International Gmbh | Method for identifying compounds altering higher-order chromatin-dependent chromosome stability |
| US20050009876A1 (en) * | 2000-07-31 | 2005-01-13 | Bhagwat Shripad S. | Indazole compounds, compositions thereof and methods of treatment therewith |
| US6352858B1 (en) * | 2000-09-11 | 2002-03-05 | Isis Pharmaceuticals, Inc. | Antisense modulation of BTAK expression |
| US6660731B2 (en) * | 2000-09-15 | 2003-12-09 | Vertex Pharmaceuticals Incorporated | Pyrazole compounds useful as protein kinase inhibitors |
| US6610677B2 (en) * | 2000-09-15 | 2003-08-26 | Vertex Pharmaceuticals Incorporated | Pyrazole compounds useful as protein kinase inhibitors |
| US7473691B2 (en) * | 2000-09-15 | 2009-01-06 | Vertex Pharmaceuticals Incorporated | Pyrazole compounds useful as protein kinase inhibitors |
| US6613776B2 (en) * | 2000-09-15 | 2003-09-02 | Vertex Pharmaceuticals Incorporated | Pyrazole compounds useful as protein kinase inhibitors |
| KR100876069B1 (ko) * | 2000-09-15 | 2008-12-26 | 버텍스 파마슈티칼스 인코포레이티드 | 단백질 키나제 억제제로서 유용한 피라졸 화합물 및 이를 포함하는 약제학적 조성물 |
| EP1345909A1 (en) * | 2000-11-27 | 2003-09-24 | Pharmacia Italia S.p.A. | Phenylacetamido-pyrazole derivatives and their use as antitumor agents |
| US6659911B2 (en) * | 2000-11-28 | 2003-12-09 | Yamaha Marine Kabushiki Kaisha | Shift assist system for an outboard motor |
| CA2432417A1 (fr) * | 2000-12-20 | 2002-06-27 | Societe De Conseils De Recherches Et D'applications Scientifiques (S.C.R .A.S.) | Inhibiteurs de kinases dependantes des cylines (cdk) et de la glycogene synthase kinase-3 (gsk-3) |
| MXPA03005610A (es) * | 2000-12-21 | 2003-10-06 | Vertex Pharma | Compuestos de pirazol utiles como inhibidores de la proteina cinasa. |
| MY130778A (en) * | 2001-02-09 | 2007-07-31 | Vertex Pharma | Heterocyclic inhibitiors of erk2 and uses thereof |
| WO2002087758A1 (en) * | 2001-04-28 | 2002-11-07 | China Petroleum & Chemical Corporation | A rare earth zeolite y and the preparation process thereof |
| CA2447405C (en) * | 2001-05-14 | 2006-10-17 | Pfizer Products Inc. | Tartrate salts of 5,8,14-triazatetracyclo[10.3.1.02,11.04,9]-hexadeca-2(11),3,5,7,9-pentaene and pharmaceutical compositions thereof |
| KR20040000507A (ko) * | 2001-05-24 | 2004-01-03 | 야마노우치세이야쿠 가부시키가이샤 | 3-퀴놀린-2(1ｈ)-일리덴인돌린-2-온 유도체 |
| MXPA03010961A (es) * | 2001-05-31 | 2004-02-27 | Vertex Pharma | Compuestos de tiazol utiles como inhibidores de proteinas cinasas. |
| DE60214703T2 (de) * | 2001-06-01 | 2007-09-13 | Vertex Pharmaceuticals Inc., Cambridge | Thiazolverbindungen, die sich als inhibitoren von proteinkinasen eignen |
| GB0115109D0 (en) * | 2001-06-21 | 2001-08-15 | Aventis Pharma Ltd | Chemical compounds |
| US6872533B2 (en) * | 2001-07-27 | 2005-03-29 | The Regents Of The University Of California | STK15 (STK6) gene polymorphism and methods of determining cancer risk |
| WO2003011287A1 (en) * | 2001-08-03 | 2003-02-13 | Vertex Pharmaceuticals Incorporated | Pyrazolon derivatives as inhibitors of gsk-3 |
| NZ530782A (en) * | 2001-08-06 | 2005-11-25 | Pharmacia Italia S | Aminoisoxazole derivatives active as kinase inhibitors |
| US20030073692A1 (en) * | 2001-08-07 | 2003-04-17 | Pharmacia & Upjohn S.P.A. | Amino-phthalazinone derivatives active as kinase inhibitors, process for their preparation and pharmaceutical compositions containing them |
| US6806272B2 (en) * | 2001-09-04 | 2004-10-19 | Boehringer Ingelheim Pharma Kg | Dihydropteridinones, processes for preparing them and their use as pharmaceutical compositions |
| WO2003024936A1 (en) * | 2001-09-19 | 2003-03-27 | Pharmacia Corporation | Substituted pyrazolo compounds for the treatment of inflammation |
| JP2005506983A (ja) * | 2001-09-19 | 2005-03-10 | ファルマシア・コーポレーション | 炎症の治療のための置換ピラゾリル化合物 |
| BR0212613A (pt) * | 2001-09-19 | 2004-08-31 | Pharmacia Corp | Compostos de indazol substituìdos para o tratamento de inflamação |
| CN1316634C (zh) * | 2001-10-03 | 2007-05-16 | 株式会社东芝 | X光平面检测器 |
| US20040010027A1 (en) * | 2001-12-17 | 2004-01-15 | Pharmacia & Upjohn Spa | Hydroxphenyl-pyrazole derivatives active as kinase inhibitors, process for their preparation and pharmaceutical comositions comprising them |
| PL211694B1 (pl) * | 2001-12-24 | 2012-06-29 | Astrazeneca Ab | Podstawiona pochodna chinazoliny, jej zastosowania oraz jej kompozycja farmaceutyczna |
| FR2836914B1 (fr) * | 2002-03-11 | 2008-03-14 | Aventis Pharma Sa | Indazoles substitues, compositions les contenant, procede de fabrication et utilisation |
| WO2003077921A1 (en) * | 2002-03-15 | 2003-09-25 | Vertex Pharmaceuticals, Inc. | Azinylaminoazoles as inhibitors of protein kinases |
| ES2289279T3 (es) * | 2002-03-15 | 2008-02-01 | Vertex Pharmaceuticals Incorporated | Composiciones utiles como inhibidores de proteinquinasas. |
| AU2003225800A1 (en) * | 2002-03-15 | 2003-09-29 | Hayley Binch | Azolylaminoazine as inhibitors of protein kinases |
| US20040009981A1 (en) * | 2002-03-15 | 2004-01-15 | David Bebbington | Compositions useful as inhibitors of protein kinases |
| AU2003237121A1 (en) * | 2002-04-26 | 2003-11-10 | Vertex Pharmaceuticals Incorporated | Pyrrole derivatives as inhibitors of erk2 and uses thereof |
| US6989451B2 (en) * | 2002-06-04 | 2006-01-24 | Valeant Research & Development | Heterocyclic compounds and uses thereof |
| MY141867A (en) * | 2002-06-20 | 2010-07-16 | Vertex Pharma | Substituted pyrimidines useful as protein kinase inhibitors |
| US7361665B2 (en) * | 2002-07-09 | 2008-04-22 | Vertex Pharmaceuticals Incorporated | Inhibitors of c-Jun N-terminal kinases (JNK) and other protein kinases |
| WO2004016597A2 (en) * | 2002-08-14 | 2004-02-26 | Vertex Pharmaceuticals Incorporated | Protein kinase inhibitors and uses thereof |
| WO2004026877A1 (en) * | 2002-09-23 | 2004-04-01 | Schering Corporation | Imidazopyrazines as cyclin dependent kinase inhibitors |
| US20040102380A1 (en) * | 2002-11-18 | 2004-05-27 | Fulton Scott P. | Method for continuous, automated blending of solutions from acids and bases |
| JP2006515014A (ja) * | 2003-01-30 | 2006-05-18 | ベーリンガー インゲルハイム ファーマシューティカルズ インコーポレイテッド | ＰＫＣ−θのインヒビターとして有用な２，４−ジアミノピリミジン誘導体 |
| US6861422B2 (en) * | 2003-02-26 | 2005-03-01 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Dihydropteridinones, processes for preparing them and their use as pharmaceutical compositions |
| RU2342365C2 (ru) * | 2003-05-01 | 2008-12-27 | Бристол-Маерс Сквибб Компани | Арилзамещенные пиразоламиды в качестве ингибиторов киназ |
| WO2005000200A2 (en) * | 2003-05-09 | 2005-01-06 | Sugen, Inc. | Novel kinases |
| PT1636225E (pt) * | 2003-06-20 | 2010-05-03 | Novartis Vaccines & Diagnostic | Compostos piridino[1,2-a]pirimidin-4-ona como agentes anti-cancerígenos |
| US20050065171A1 (en) * | 2003-06-25 | 2005-03-24 | Shakespeare William C. | Substituted purine derivatives |
| US20050032869A1 (en) * | 2003-07-08 | 2005-02-10 | Pharmacia Italia S.P.A. | Pyrazolyl-indole derivatives active as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them |
| US7141568B2 (en) * | 2003-07-09 | 2006-11-28 | Pfizer Italia S.R.L. | Pyrrolo[3,4-c]pyrazole derivatives active as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them |
| US20050026984A1 (en) * | 2003-07-29 | 2005-02-03 | Aventis Pharma S.A. | Substituted thieno [2,3-c] pyrazoles and their use as medicinal products |
| US7094791B2 (en) * | 2003-07-31 | 2006-08-22 | Avalon Pharmaceuticals, Inc. | Derivatives of 3-hydroxy-pyrrole-2,4-dicarboxylic acid and uses thereof |
| US7279575B2 (en) * | 2003-08-08 | 2007-10-09 | Pfizer Italia S.R.L. | Pyrimidylpyrrole derivatives active as kinase inhibitors |
| US20050043346A1 (en) * | 2003-08-08 | 2005-02-24 | Pharmacia Italia S.P.A. | Pyridylpyrrole derivatives active as kinase inhibitors |
| US7157476B2 (en) * | 2003-08-20 | 2007-01-02 | Vertex Pharmaceuticals Incorporated | Aminofurazan compounds useful as protein kinase inhibitors |
| US20050085531A1 (en) * | 2003-10-03 | 2005-04-21 | Hodge Carl N. | Thiophene-based compounds exhibiting ATP-utilizing enzyme inhibitory activity, and compositions, and uses thereof |
| US20050107386A1 (en) * | 2003-11-19 | 2005-05-19 | Rama Krishna Narla | Methods of treating diseases and disorders by targeting multiple kinases |
| FR2865934B1 (fr) * | 2004-02-05 | 2006-05-05 | Sanofi Synthelabo | Utilisation de derives d'indolizine 1,2,3 substitues, inhibiteurs des fgfs, pour la preparation de medicaments utiles pour le traitement de maladies liees a une angiogenese pathologique choroidienne |
| TW200536536A (en) * | 2004-02-25 | 2005-11-16 | Schering Corp | Pyrazolotriazines as kinase inhibitors |
| FR2868421B1 (fr) * | 2004-04-01 | 2008-08-01 | Aventis Pharma Sa | Nouveaux benzothiazoles et leur utilisation comme medicaments |
| FR2871158A1 (fr) * | 2004-06-04 | 2005-12-09 | Aventis Pharma Sa | Indazoles substitues, compositions les contenant, procede de fabrication et utilisation |
| DE102004029784A1 (de) * | 2004-06-21 | 2006-01-05 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Neue 2-Benzylaminodihydropteridinone, Verfahren zur deren Herstellung und deren Verwendung als Arzneimittel |
| DE102004034623A1 (de) * | 2004-07-16 | 2006-02-02 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Neue 6-Formyl-tetrahydropteridine, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel |
| US7521457B2 (en) * | 2004-08-20 | 2009-04-21 | Boehringer Ingelheim International Gmbh | Pyrimidines as PLK inhibitors |
| JP2008510770A (ja) * | 2004-08-26 | 2008-04-10 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | Ｐｌｋ阻害剤としての新規プテリジノン |
| WO2006021548A1 (de) * | 2004-08-27 | 2006-03-02 | Boehringer Ingelheim International Gmbh | Dihydropteridinone, verfahren zu deren herstellung und deren verwendung als arzneimittel |
| FR2876377B1 (fr) * | 2004-10-11 | 2007-03-16 | Univ Claude Bernard Lyon | Nouveaux derives de 9h-pyrido[2,3-b]indole, leur procede de preparation, ainsi que les compositions pharmaceutiques contenant de tels composes |
| MX2007004403A (es) * | 2004-10-12 | 2007-04-27 | Astrazeneca Ab | Derivados de quinazolina. |
| FR2882751B1 (fr) * | 2005-03-04 | 2007-09-14 | Aventis Pharma Sa | Hydrazinocarbonyl-thieno[2,3-c]pyrazoles, procede de preparation, compositions les contenant et utilisation |
| FR2884821B1 (fr) * | 2005-04-26 | 2007-07-06 | Aventis Pharma Sa | Pyrrolopyridines substitues, compositions les contenant, procede de fabrication et utilisation |
| CA2610347A1 (en) * | 2005-06-09 | 2006-06-08 | Boehringer Ingelheim International Gmbh | Alpha-carbolines as cdk-1 inhibitors |
| US8119655B2 (en) * | 2005-10-07 | 2012-02-21 | Takeda Pharmaceutical Company Limited | Kinase inhibitors |
| AU2007313961A1 (en) * | 2006-10-09 | 2008-05-08 | Takeda Pharmaceutical Company Limited | Kinase inhibitors |
| US20090312288A1 (en) * | 2008-04-16 | 2009-12-17 | Takeda Pharmaceutical Company Limited | Kinase inhibitors |
-
2007
- 2007-10-08 JP JP2009532518A patent/JP2010505961A/ja active Pending
- 2007-10-08 EP EP10165143A patent/EP2223925A1/en not_active Withdrawn
- 2007-10-10 PE PE2007001361A patent/PE20081458A1/es not_active Application Discontinuation
- 2007-10-10 AR ARP070104481A patent/AR063232A1/es unknown
- 2007-10-10 CL CL200702919A patent/CL2007002919A1/es unknown
- 2007-10-11 TW TW096138101A patent/TW200823212A/zh unknown
-
2008
- 2008-04-15 US US12/103,625 patent/US20090156557A1/en not_active Abandoned
-
2010
- 2010-02-17 US US12/706,837 patent/US20100160633A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| CL2007002919A1 (es) | 2008-03-14 |
| EP2223925A1 (en) | 2010-09-01 |
| US20090156557A1 (en) | 2009-06-18 |
| TW200823212A (en) | 2008-06-01 |
| PE20081458A1 (es) | 2008-12-03 |
| JP2010505961A (ja) | 2010-02-25 |
| US20100160633A1 (en) | 2010-06-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR063232A1 (es) | Pirido (2,3) indoles como inhibidores de quinasas.composiciones farmaceuticas. | |
| AR069462A1 (es) | Inhibidores de mapk/ erk quinasa | |
| CO6321274A2 (es) | Compuestos de pirazol acetamida n-sustituida como activadores de glucoquinasa | |
| AR071729A1 (es) | Inhibidores de quinasas simil polo (plk) | |
| AR072936A1 (es) | Derivados piridazin y pirimidin condensados con heterociclos nitrogenados, composiciones farmaceuticas que los contienen y uso de los mismos como agentes anticancer. | |
| CO6230984A2 (es) | Inhibidores de cinasa mapk/erk | |
| RS53176B (en) | KINASE INHIBITORS 1 REGULATING SIGNALS IN APOPTOSIS | |
| AR048362A1 (es) | Derivados de tetrahidronaftiridina y proceso para la preparacion de los mismos | |
| PE20130155A1 (es) | Derivados de ariletinilo | |
| AR085615A1 (es) | Derivados de fluoropiridinona utiles como agentes antibacterianos y composiciones farmaceuticas que los contienen | |
| CO6260009A2 (es) | Derivados de ariloxiacetamida bi-o triciclicos saturados e insaturados y su uso como fungicidas | |
| AR061369A1 (es) | Derivados de pirimidina y composiciones farmaceuticas que los comprenden | |
| AR071452A1 (es) | Inhibidores de hsp90 | |
| CO6241101A2 (es) | Derivados de quinolina como inhibidores de la p13 quinasa | |
| AR075854A1 (es) | Inhibidores de beta- secretasa | |
| AR083069A1 (es) | Analogos de nucleotidos sustituidos | |
| ES2613538T3 (es) | Derivados de arilamida como bloqueadores de TTX-S | |
| AR044519A1 (es) | Derivados de piridin-tiazol amina y de pirimidin-tiazol amina | |
| CO6150145A2 (es) | Derivados de aril/heterociclo/cicloalquil/cicloalquil fenil substituidos utiles como agentes inmunosupresores | |
| WO2010005534A3 (en) | Proteasome inhibitors for selectively inducing apoptosis in cancer cells | |
| AR087919A1 (es) | Heterociclos biciclicos como inhibidores de irak4 | |
| AR045455A1 (es) | Derivados de pirimidina como inhibidores de dipeptidil peptidasa | |
| AR094262A1 (es) | Compuestos antivirales para el tratamiento de la hepatitis c | |
| AR077695A1 (es) | Derivados de pirimidina como inhibidores del factor ixa | |
| AR069740A1 (es) | Compuestos nucleosidos antivirales |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |